All In Biotech

Drug Trial Radar · NCT00434824

Effects of Andriol Testocaps in Symptomatic Late-Onset Hypogonadism (43203)

A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Oral Administration of Different Doses of Org 538 in Symptomatic Aging Men With Androgen Deficiency

Last checked: Nov 19, 2026Latest source record: Apr 16, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 322 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

322

Actual

Start

Nov 2001

Primary completion

Jul 2004

Study completion Jul 2004

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Feb 13, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Male only, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study we have evaluated the effects of three different doses of oral testosterone undecanoate in aging men presenting with a combination of symptoms suggestive of hypogonadism and low blood levels of the male hormone testosterone. Specifically, we have studied the effects on: * symptoms suggestive of low testosterone levels * blood testosterone and other hormone levels * bone mass * muscle mass and fat mass * muscle strength * prostate * lipids, hematocrit

Conditions

  • Hypogonadism
  • Androgens

Interventions

  • Oral testosterone undecanoate (Andriol)Drug

    treatment for 12 months with oral TU 80 mg/d, oral TU 160 mg/d or oral TU 240 mg/d in divided doses

  • PlaceboDrug

    treatment for 12 months with placebo in divided doses

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline on the total score of the AMS rating scaleTime frame: Month 6

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.